在封闭的解冻虹吸系统中，由去氨加压素刺激的献血者血浆制备的中等纯度冷沉淀。

Cryoprecipitate of intermediate purity produced in a closed thaw-siphon system from DDAVP stimulated blood donor plasma.

作者信息

Konecka G, Bykowska K, Ludwicka A, Letowska M, Wegrzynowicz Z, Sablinski J, Lopaciuk S

机构信息

Department of Blood Storage and Preparation, Institute of Haematology, Warsaw, Poland.

出版信息

Folia Haematol Int Mag Klin Morphol Blutforsch. 1990;117(4):565-70.

PMID:1714861

Abstract

The effects of intravenous administration of DDAVP to blood donors and the use of DDAVP plasma for the production of cryoprecipitate in the closed thaw-siphon system were evaluated. DDAVP treatment produced on the average a 3.2-fold rise in plasma levels of factor VIII. Von Willebrand factor antigen increased to a lesser extent. Cryoprecipitate prepared from 220-280 ml aliquots of DDAVP stimulated donor plasma contained 472 +/- 210 units of factor VIII and 276 +/- 130 units of von Willebrand factor antigen. The average yield of factor VIII was 57% of that in the prefrozen plasma. The specific activity of factor VIII in cryoprecipitate was 0.77 +/- 0.44 U/mg protein, comparable to that for intermediate purity concentrates. Thus, by the use of DDAVP and the thaw-siphon technique it is possible to produce cryoprecipitate 4-7 times as potent as conventionally manufactured preparations.

摘要

评估了对献血者静脉注射去氨加压素（DDAVP）的效果以及在封闭式解冻虹吸系统中使用DDAVP处理过的血浆生产冷沉淀的情况。DDAVP治疗使血浆中凝血因子VIII水平平均升高了3.2倍。血管性血友病因子抗原升高幅度较小。从220 - 280毫升经DDAVP刺激的献血者血浆制备的冷沉淀含有472±210单位的凝血因子VIII和276±130单位的血管性血友病因子抗原。凝血因子VIII的平均产量为预冻血浆中产量的57%。冷沉淀中凝血因子VIII的比活性为0.77±0.44 U/mg蛋白质，与中等纯度浓缩物相当。因此，通过使用DDAVP和解冻虹吸技术，可以生产出效力比传统制备方法高4 - 7倍的冷沉淀。